3-Hydroxy-3-methylglutaric and 3-methylglutaric acids impair redox status and energy production and transfer in rat heart: relevance for the pathophysiology of cardiac dysfunction in 3-hydroxy-3-methylglutaryl-coenzyme A lyase deficiency.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
intraperitoneal administration of HMG | decrease | activities of the respiratory chain complex II | rat heart | - | decreased | #1 |
intraperitoneal administration of HMG | decrease | creatine kinase (CK) activity | rat heart | - | decreased | #2 |
intraperitoneal administration of HMG | decrease | activity of complex II-III | rat heart | - | decreased | #3 |
intraperitoneal administration of MGA | decrease | activities of the respiratory chain complex II | rat heart | - | decreased | #4 |
intraperitoneal administration of MGA | decrease | creatine kinase (CK) activity | rat heart | - | decreased | #5 |
intraperitoneal administration of HMG | increase | reactive species production | rat heart | - | increased | #6 |
intraperitoneal administration of HMG | increase | carbonyl formation | rat heart | - | increased | #7 |
intraperitoneal administration of HMG | decrease | glutathione concentrations | rat heart | - | decreased | #8 |
intraperitoneal administration of MGA | increase | reactive species production | rat heart | - | increased | #9 |
intraperitoneal administration of MGA | increase | carbonyl formation | rat heart | - | increased | #10 |
intraperitoneal administration of MGA | decrease | glutathione concentrations | rat heart | - | decreased | #11 |
intraperitoneal administration of HMG | increase | glutathione peroxidase (GPx) activity | rat heart | - | increased | #12 |
intraperitoneal administration of HMG | increase | glutathione reductase (GR) activity | rat heart | - | increased | #13 |
intraperitoneal administration of MGA | increase | glutathione peroxidase (GPx) activity | rat heart | - | increased | #14 |
intraperitoneal administration of MGA | increase | glutathione reductase (GR) activity | rat heart | - | increased | #15 |
intraperitoneal administration of MGA | decrease | activities of superoxide dismutase (SOD) | rat heart | - | diminished | #16 |
intraperitoneal administration of MGA | decrease | catalase activity | rat heart | - | diminished | #17 |
intraperitoneal administration of MGA | decrease | protein content of SOD1 | rat heart | - | diminished | #18 |
Pre-treatment with melatonin (MEL) | no change | MGA-induced decrease of CK activity | rat heart | - | prevented | #19 |
Pre-treatment with melatonin (MEL) | no change | MGA-induced decrease of SOD1 levels | rat heart | - | prevented | #20 |
HMG | increase | reactive species formation | in vitro models | - | increased | #21 |
HMG | increase | lipid peroxidation | in vitro models | - | induced | #22 |
HMG | decrease | glutathione | in vitro models | - | decreased | #23 |
MGA | increase | reactive species formation | in vitro models | - | increased | #24 |
MGA | increase | lipid peroxidation | in vitro models | - | induced | #25 |
MGA | decrease | glutathione | in vitro models | - | decreased | #26 |
melatonin (MEL) | no change | reactive species overproduction provoked by HMG | in vitro models | - | abrogated | #27 |
melatonin (MEL) | no change | glutathione decrease provoked by HMG | in vitro models | - | abrogated | #28 |
melatonin (MEL) | no change | reactive species overproduction provoked by MGA | in vitro models | - | abrogated | #29 |
melatonin (MEL) | no change | glutathione decrease provoked by MGA | in vitro models | - | abrogated | #30 |
lipoic acid (LA) | no change | reactive species overproduction provoked by HMG | in vitro models | - | abrogated | #31 |
lipoic acid (LA) | no change | glutathione decrease provoked by HMG | in vitro models | - | abrogated | #32 |
lipoic acid (LA) | no change | reactive species overproduction provoked by MGA | in vitro models | - | abrogated | #33 |
lipoic acid (LA) | no change | glutathione decrease provoked by MGA | in vitro models | - | abrogated | #34 |
melatonin (MEL) | no change | HMG-induced lipoperoxidation | in vitro models | - | prevented | #35 |
melatonin (MEL) | no change | MGA-induced lipoperoxidation | in vitro models | - | prevented | #36 |
Allopurinol (ALP) | no change | reactive species overproduction caused by HMG | in vitro models | - | prevented | #37 |
Allopurinol (ALP) | no change | reactive species overproduction caused by MGA | in vitro models | - | prevented | #38 |
3-Hydroxy-3-methylglutaryl-coenzyme A lyase (HL) deficiency is characterized by tissue accumulation of 3-hydroxy-3-methylglutaric (HMG), and 3-methylglutaric (MGA) acids. Affected patients present cardiomyopathy, whose pathomechanisms are not yet established. We investigated the effects of HMG and MGA on energy and redox homeostasis in rat heart using in vivo and in vitro models. In vivo experiments showed that intraperitoneal administration of HMG and MGA decreased the activities of the respiratory chain complex II and creatine kinase (CK), whereas HMG also decreased the activity of complex II-III. Furthermore, HMG and MGA injection increased reactive species production and carbonyl formation, and decreased glutathione concentrations. Regarding the enzymatic antioxidant defenses, HMG and MGA increased glutathione peroxidase (GPx) and glutathione reductase (GR) activities, while only MGA diminished the activities of superoxide dismutase (SOD) and catalase, as well as the protein content of SOD1. Pre-treatment with melatonin (MEL) prevented MGA-induced decrease of CK activity and SOD1 levels. In vitro results demonstrated that HMG and MGA increased reactive species formation, induced lipid peroxidation and decreased glutathione. We also verified that reactive species overproduction and glutathione decrease provoked by HMG and MGA were abrogated by MEL and lipoic acid (LA), while only MEL prevented HMG- and MGA-induced lipoperoxidation. Allopurinol (ALP) also prevented reactive species overproduction caused by both metabolites. Our data provide solid evidence that bioenergetics dysfunction and oxidative stress are induced by HMG and MGA in heart, which may explain the cardiac dysfunction observed in HL deficiency, and also suggest that antioxidant supplementation could be considered as adjuvant therapy for affected patients.